Compare VanEck Semiconductor ETF (SMH) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Semiconductor ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? VanEck Semiconductor ETF trades at $604.13 (market cap $73.92B), while Vertex Pharmaceuticals Incorporated trades at $509.57 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and VanEck Semiconductor ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Semiconductor ETF for 101 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SMH | VRTX | |
|---|---|---|
Market Cap | $73.92B | $127.55B |
Volume | 11,050,892 | 1,487,944 |
52-Week High | $668.91 | $557.96 |
52-Week Low | $325.10 | $407.37 |
Typical Hold Time | 101 Days | 120 Days |
Sector | — | Health |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMH (VanEck Semiconductor ETF) trades at $606.11, down 3.03% on the day, but maintains a strong bullish technical outlook with moving averages signaling continued strength. The ETF has delivered exceptional 69% returns year-to-date through September 30, 2026, significantly outperforming major semiconductor holdings like Nvidia. Recent sector momentum is supported by positive industry developments including AMD's $8.2 billion acquisition of World Labs and Bank of America's projection that the global chip market will nearly double by 2030.
The semiconductor sector's structural growth drivers, particularly in AI hardware, support continued ETF appreciation, though concentration risk in top holdings and elevated RSI levels near 76 suggest potential near-term consolidation. Investors benefit from diversified exposure to the physical AI infrastructure boom, but should monitor valuation metrics as the sector trades at elevated levels following substantial gains.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
